VCM
IMNM icon

Versant Capital Management’s Immunome IMNM Stock Holding History

Versant Capital Management’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,170
Closed -$7.87K – 2678
2025
Q1 		$7.87K Buy
+1,170
New +$11.2K ﹤0.01% 1837

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Versant Capital Management's IMNM Position: Q2 2025 in Review

Versant Capital Management sold out of Immunome (IMNM) in Q2 2025, closing a stake of 1,170 shares — an estimated $7.87K sold.

Versant Capital Management first reported a position in IMNM in Q1 2025 and held it in 1 quarter. The position peaked at $7.87K in Q1 2025. 142 funds tracked by Wall St. Rank hold IMNM as of Q2 2025.

  • Versant Capital Management reported no remaining Immunome position as of Q2 2025 after selling out during the quarter.
  • Versant Capital Management sold 1,170 Immunome shares in Q2 2025, an estimated $7.87K.
  • Versant Capital Management first reported a position in Immunome in Q1 2025 and held it in 1 quarter.
  • Versant Capital Management's Immunome position peaked at $7.87K in Q1 2025.
  • 142 funds tracked by Wall St. Rank held Immunome as of Q2 2025.

Based on Versant Capital Management's 13F filing for Q2 2025, filed 7 Jul 2025.